What is the role of the D3 receptor in addiction? A mini review of PET studies with [11C]-(+)-PHNO

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 52, Issue , 2014, Pages 4-8

  Payer, Doris ^a,b   Balasubramaniam, Gayathiri ^a   Boileau, Isabelle ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Addiction; Positron emission tomography

Indexed keywords

BUSPIRONE; CARBON PROPYL HEXAHYDRO NAPHTO OXAZIN C 11; DOPAMINE 3 RECEPTOR; GSK 598809; RADIOLIGAND; UNCLASSIFIED DRUG; DOPAMINE RECEPTOR STIMULATING AGENT; NAXAGOLIDE; OXAZINE DERIVATIVE;

ARTICLE; CLINICAL TRIAL (TOPIC); COCAINE DEPENDENCE; CONNECTOME; DOPAMINE BRAIN LEVEL; DOPAMINE RECEPTOR BLOCKING; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; HUMAN; METHAMPHETAMINE DEPENDENCE; MOTIVATION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RECEPTOR UPREGULATION; SUBSTANCE ABUSE; ADDICTION; BRAIN; DRUG EFFECTS; METABOLISM; SCINTISCANNING;

BRAIN; DOPAMINE AGONISTS; HUMANS; OXAZINES; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE D3; SUBSTANCE-RELATED DISORDERS;

EID: 84899634813     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.08.012     Document Type: Article

References (74)

1. 11C]-(+)-PHNO PET by ABT-925. Neuroimage 2008, 48:39.
2. 3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 2003, 28:1272-1280.
3. 3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse 2003, 48:154-156.
4. 3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder. J Pharmacol Exp Ther 2013, 344:501-510.
5. 4 dopamine receptors. Int J Neuropsychopharmacol 2013, 16:445-458.
6. 11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci 2012, 32:1353-1359.
7. 11C]raclopride. Addiction 2013, 108:953-963.
8. 3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci U S A 1997, 94:3363-3367.
9. 2 receptor mRNA. Brain Res 1991, 564:203-219.
10. Brand M., Labudda K., Kalbe E., Hilker R., Emmans D., Fuchs G., et al. Decision-making impairments in patients with Parkinson's disease. Behav Neurol 2004, 15:77-85.
11. Chiang Y.C., Chen P.C., Chen J.C. D(3) dopamine receptors are down-regulated in ampethamine sensitized rats and their putative antagonists modulate the locomotor sensitization to amphetamine. Brain Res 2003, 972:159-167.
12. 3 receptor availability. Cereb Cortex 2012, 22:2784-2793.
13. 3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci 2000, 20:8677-8684.
14. D'Sa C., Fox H.C., Hong A.K., Dileone R.J., Sinha R. Increased serum brain-derived neurotrophic factor is predictive of cocaine relapse outcomes: a prospective study. Biol Psychiatry 2011, 70:706-711.
15. 2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry 2008, 165:507-514.
16. Frankel P.S., Alburges M.E., Bush L., Hanson G.R., Kish S.J. Brain levels of neuropeptides in human chronic methamphetamine users. Neuropharmacology 2007, 53:447-454.
17. Frankel P.S., Alburges M.E., Bush L., Hanson G.R., Kish S.J. Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users. Neuropharmacology 2008, 55:41-46.
18. 3 dopamine receptor. J Pharmacol Exp Ther 1994, 268:417-426.
19. 2 receptors in vivo using positron emission tomography. J Neurochem 2006, 97:1089-1103.
20. Graff-Guerrero A., Willeit M., Ginovart N., Mamo D., Mizrahi R., Rusjan P., et al. Brain region binding of the D(2/3) agonist [(11)C]-(+)-PHNO and the D(2/3) antagonist [(11)C]raclopride in healthy humans. Hum Brain Mapp 2008, 29:400-410.
21. 3 receptor expression and triggers behavioural sensitization. Nature 2001, 411:86-89.
22. 3 receptor expression: therapeutic implications in Parkinson's disease. Eur J Pharmacol 2003, 480:89-95.
23. Heidbreder C.A., Newman A.H. Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann N Y Acad Sci 2010, 1187:4-34.
24. Kalivas P.W., Lalumiere R.T., Knackstedt L., Shen H. Glutamate transmission in addiction. Neuropharmacology 2009, 56(Suppl. 1):169-173.
25. Kim D.J., Roh S., Kim Y., Yoon S.J., Lee H.K., Han C.S., et al. High concentrations of plasma brain-derived neurotrophic factor in methamphetamine users. Neurosci Lett 2005, 388:112-115.
26. 3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacology 2003, 28:839-849.
27. Le Foll B., Boileau I. Repurposing buspirone for drug addiction treatment. Int J Neuropsychopharmacol 2013, 16:251-253.
28. Le Foll B., Goldberg S.R. Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology (Berl) 2006, 184:367-381.
29. 3 receptor in reactivity to cocaine-associated cues in mice. Eur J Neurosci 2002, 15:2016-2026.
30. 3 receptor expression: implications for drug-conditioning. Neuroreport 2005, 16:175-178.
31. 3 receptor and drug dependence: effect on reward or beyond?. Neuropharmacology 2005, 49:525-541.
32. Lesieur H.R., Blume S.B. The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers. Am J Psychiatry 1987, 144:1184-1188.
33. 3H]hydroxy-N, N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci U S A 1992, 89:8155-8159.
34. Loiseau F., Millan M.J. Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists. Eur Neuropsychopharmacol 2009, 19:23-33.
35. Martinez D., Narendran R., Foltin R.W., Slifstein M., Hwang D.R., Broft A., et al. Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry 2007, 164:622-629.
36. 3 dopamine and kappa opioid receptor alterations in human brain of cocaine-overdose victims. Ann N Y Acad Sci 1999, 877:507-522.
37. 2 receptor binding in cocaine dependent humans. J Nucl Med Meet Abstr 2011, 52:1284.
38. Mello N.K., Fivel P.A., Kohut S.J. Effects of chronic buspirone treatment on nicotine and concurrent nicotine+cocaine self-administration. Neuropsychopharmacology 2013, 38:1264-1275.
39. Mello N.K., Fivel P.A., Kohut S.J., Bergman J. Effects of chronic buspirone treatment on cocaine self-administration. Neuropsychopharmacology 2013, 38:455-467.
40. Mogg K., Bradley B.P., O'Neill B., Bani M., Merlo-Pich E., Koch A., et al. Effect of dopamine D(3) receptor antagonism on approach responses to food cues in overweight and obese individuals. Behav Pharmacol 2012, 23:603-608.
41. 3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur J Neurosci 1998, 10:2565.
42. 3 receptors and drug craving: a translational approach. Neuropsychopharmacology 2013, 38:302-312.
43. 3 receptor preferring agonist in vivo. Synapse 2006, 60:485-495.
44. Nathan P.J., O'Neill B.V., Mogg K., Bradley B.P., Beaver J., Bani M., et al. The effects of the dopamine D(3) receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects. Int J Neuropsychopharmacol 2012, 15:149-161.
45. 3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior. Neuropsychopharmacology 2004, 29:1479-1487.
46. 3 receptor hypothesis. Biochem Pharmacol 2012, 84:882-890.
47. Payer D.E., Behzadi A., Kish S.J., Houle S., Wilson A.A., Rusjan P.M., et al. Heightened D dopamine receptor levels in cocaine dependence and contributions to the addiction behavioural phenotype: a positron emission tomography study with [C]-(+)-PHNO. Neuropsychopharmacology 2013, (in press, Epub. ahead of print).
48. Pickens C.L., Airavaara M., Theberge F., Fanous S., Hope B.T., Shaham Y. Neurobiology of the incubation of drug craving. Trends Neurosci 2011, 34:411-420.
49. 2 components of ex vivo regional (+)-PHNO brain binding in wild-type and knock-out mice. J Nucl Med 2007, 48:113.
50. 11C]PHNO in the primate brain. Neuroimage 2008, 41:T39.
51. 11C]PHNO and SB-277011. J Nucl Med 2008, 49:80.
52. 3 dopamine receptor-mediated inhibitory function. Neuropsychopharmacology 2006, 31:2368-2375.
53. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 1993, 18:247-291.
54. 3 receptor antagonist SB-277011A on the reinforcing effects of nicotine as measured by a progressive-ratio schedule in rats. Eur J Pharmacol 2007, 559:173-179.
55. 3 receptor antagonist. Biol Psychiatry 2010, 68:392-399.
56. 3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Brain Res Mol Brain Res 1997, 45:335-339.
57. Shotbolt P., Tziortzi A.C., Searle G.E., Colasanti A., van der Aart J., Abanades S., et al. Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans. J Cereb Blood Flow Metab 2012, 32(1):127-136.
58. 3) as a target for neuroleptics. Nature 1990, 347:146.
59. 3 dopamine receptor. Arzneimittelforschung 1992, 42:224.
60. 3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006, 5:25-43.
61. 3 dopamine receptor mRNA in dopaminergic and dopaminoceptive regions of the rat brain in response to morphine. Brain Res Mol Brain Res 2003, 111:74-83.
62. 3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 1996, 16:6100-6106.
63. 3 receptors on dopaminergic and nondopaminergic cell bodies and terminals. J Pharmacol Exp Ther 2000, 295:1223-1231.
64. 2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 2007, 30:228-235.
65. 3 receptor antagonist SB-277011-A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats. Pharmacol Biochem Behav 2005, 81:190-197.
66. 3 signal and anatomy. Neuroimage 2011, 54:264-277.
67. 3 receptor plays an essential role in alcohol-seeking and relapse. FASEB J 2006, 20:2223-2233.
68. Volkow N.D., Fowler J.S., Wang G.J., Swanson J.M., Telang F. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol 2007, 64:1575-1579.
69. Volkow N.D., Fowler J.S., Wang G.J., Baler R., Telang F. Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 2009, 56(Suppl. 1):3-8.
70. 3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J Neurosci 2002, 22:9595-9603.
71. 11C]-(+)-PHNO. Biol Psychiatry 2006, 59:389-394.
72. 2 high-affinity state with positron emission tomography. J Med Chem 2005, 48:4153.
73. 3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology (Berl) 2004, 176:57-65.
74. 3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats. Eur J Neurosci 2005, 21:3427-3438.